Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Ltd (ATHE) is a clinical-stage biotechnology company pioneering treatments for neurodegenerative disorders including Parkinson's and Alzheimer's diseases. This page serves as the definitive source for verified updates on the company's therapeutic developments, research milestones, and strategic initiatives.
Investors and researchers will find timely updates on ATH434 clinical trials, partnership announcements with leading medical institutions, and regulatory progress for novel drug candidates. Our curated news collection provides essential context for understanding Alterity's approach to targeting iron dysregulation in neurological conditions and its broader research pipeline.
Key content includes updates on:
- Phase I/II clinical trial results
- Collaborative research initiatives
- Peer-reviewed study publications
- Regulatory pathway developments
- Scientific conference presentations
Bookmark this page for structured access to Alterity Therapeutics' latest advancements in neuroprotective therapies. Check regularly for objective reporting on the company's progress in addressing complex neurodegenerative challenges through innovative biomedical research.
Rhea-AI Summary
Alterity Therapeutics CEO to participate in ShareCafe Hidden Gems webinar on February 1 and 2, 2024, for Australian and US participants, offering an archived replay. The event aims to provide further details on the company's disease modifying treatments for neurodegenerative diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ATHE) has issued a letter to shareholders outlining key milestones for 2024, including the completion of the ATH434-201 study in November 2024 and the expected preliminary data from the ATH434-202 study in 1H 2024. The company remains committed to developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA), and is focused on their lead clinical development candidate, ATH434. The drug has been granted Orphan Drug Designation (ODD) for the treatment of MSA by the U.S. FDA and the European Commission, and the primary Phase 2 clinical trial (ATH434-201) is treating participants for 12 months, with topline results expected in January 2025. Additionally, a second Phase 2 clinical trial (ATH434-202) is ongoing, with preliminary six-month data expected in the first half of this year. The company is also conducting the bioMUSE Natural History study, which continues to generate invaluable data related to the understanding of MSA and its early presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the appointment of Phillip Hains as the new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has almost 30 years of experience in corporate secretarial, accounting, and general management. This follows the resignation of Kathryn Andrews, who has been CFO since 2014. The company expressed deep appreciation for Kathryn's contributions and looks forward to expanding the relationship with Phillip in 2024, a pivotal year for Alterity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will be hosting an investor webcast to discuss the ATH434 efficacy data in primates and recent clinical progress. The webcast will be held on December 6, 2023, for Australia participants and December 5, 2023, for the United States participants. Registration is required, and investors can submit questions in advance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.86%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced promising new data on the effect of ATH434 in a Parkinson’s disease primate model, demonstrating improved motor performance and general function. The study compared daily oral doses of ATH434 versus a placebo, showing stable or improving Parkinson Behavior Rating Scale scores in ATH434-treated monkeys, indicating reduced motor impairment and improved general functions. A webcast will be held to discuss the new data and recent clinical progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
153.01%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ATH) presented findings from the Biomarkers of progression in Multiple System Atrophy (bioMUSE) Natural History Study at the 34th International Symposium on the Autonomic Nervous System. The study revealed a potential biomarker, N-acetylaspartate (NAA), for assessing disease severity and treatment response in MSA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
News
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced promising new data related to ATH434, a potential treatment for neurodegenerative diseases, presented at the Society for Neuroscience. The study shows ATH434's ability to preserve mitochondrial function and exert direct anti-oxidant activity, highlighting its potential for treating Parkinson's disease and related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has completed enrolment in its ATH434-201 Phase 2 clinical trial for early-stage multiple system atrophy (MSA), a significant milestone for developing disease modifying treatments for neurodegenerative diseases. The trial, conducted globally, exceeded its enrolment target and is expected to conclude in the fourth quarter of 2024, with results clarifying the path for potential approval of ATH434.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.77%
Tags
-
Rhea-AI Summary
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has made significant developments in the first quarter of FY24. The participant screening for the ATH434-201 Phase 2 study has been closed, and the independent Data Monitoring Committee has recommended the study to continue as planned. The company has received a cash refund of A$4.74M under the Australian R&DTI Scheme. Data presentations from Alterity's bioMUSE natural history study of Multiple System Atrophy were delivered at the International Congress of Parkinson's Disease and Movement Disorders. The company has also been granted a new composition of matter patent by the European Patent Office. Alterity's cash balance on September 30, 2023, was A$16.7M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
News
Rhea-AI Summary
Alterity Therapeutics presented data from its bioMUSE study of Multiple System Atrophy (MSA) at the International Congress of Parkinson’s Disease and Movement Disorders. The presentations highlighted the importance of incorporating biomarkers for accurate diagnosis of MSA. The use of a diverse set of biomarkers was shown to improve diagnostic accuracy in early MSA. Specialized MRI techniques and fluid biomarkers were found to enhance specificity of MSA diagnosis and assess disease severity and treatment response. The findings support the application of clinical and quantitative biomarkers in clinical trials for early MSA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Alterity Therapeutics Ltd